During embryogenesis, a C. elegans embryo must first assess its genetic dosage of X chromosomes, and then develop accordingly as male (XO) or hermaphrodite (XX). This development involves not only morphological sexual differentiation, but also implementation of X-chromosome dosage compensation, an essential process. Dosage compensation in worms is achieved by repressing the level of X expression by half in XX animals. Genetic screens for sex-specific lethality have been a successful approach to dissecting the pathway involved in counting the number of X chromosomes (X-signal elements
fox-1 and
sex-1 ), and in implementing the consequences of that counting process (the sdc genes, and dosage compensation-specific genes). The target of the counting process is the
xol-1 gene, which coordinates sexual morphology with dosage compensation.
xol-1 XO mutants inappropriately activate the hermaphrodite mode of development--they are feminized, and die due to underexpression of X-linked genes. Interestingly, in addition to its essential role in XO animals,
xol-1 has a secondary role in the feminization of XX animals. 1 The maternal-effect autosomal mutation
y2 was isolated in a screen for sex-specific phenotypes and exhibits XO-specific embryonic lethality. Unlike
xol-1 mutants,
y2 mutants exhibit reduced expression from the X chromosome in both XX and XO karyotypes. XX hermaphrodites have phenotypes that are consistent with perturbed expression from X. Therefore,
y2 XO animals could suffer from reduced gene expression below a critical threshold, and die as a result. However, overexpression of
xol-1 from a ubiquitously expressed promoter can rescue
y2 XO lethality, whereas the XX lethality from overexpression of
xol-1 is not rescued by
y2 . This result suggests that
y2 does impinge on the regulatory pathway for sex determination and dosage compensation. Surprisingly, the rescued animals are feminized, a phenotype not seen when
xol-1 is overexpressed in a wild-type XO background. Paradoxically, staining of dying
y2 XO embryos with antibodies against the dosage compensation complex indicates that the complex is not localized to X, as it is in dying
xol-1 XO embryos. At this time, no simple explanation can be found for the role of
y2 , but we are intrigued by the possibilities.
y2 may generally regulate gene expression, act as an autosomal signal element, be involved in the coordinate control of dosage compensation and sexual differentiation, or function with
xol-1 to specify sexual differentiation. Currently, efforts are being taken to map and clone
y2 , and genetic and molecular experiments are being performed to address how this mutation may act on known genes in the pathway. 1 Miller, L.M., Plenefisch, J.D., Casson, L.P., and Meyer, B.J. (1988). Cell 55, 167-183.